Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03385226
Title A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT)
Acronym PORT
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.